BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination

BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination

Activation of farnesoid X receptor (FXR) by obeticholic acid (OCA) reduces hepatic inflammation and fibrosis in patients with primary biliary cholangitis (PBC), a life-threatening cholestatic liver failure. Inhibition of bromodomain-containing protein 4 (BRD4) also has antiinflammatory, antifibrotic...

Full description

Bibliographic Details
Main Authors: Hyunkyung Jung, Jinjing Chen, Xiangming Hu, Hao Sun, Shwu-Yuan Wu, Cheng-Ming Chiang, Byron Kemper, Lin-Feng Chen, Jongsook Kim Kemper
Format: Article
Language:English
Published: American Society for Clinical investigation 2021-01-01
Series:JCI Insight
Subjects:
Hepatology
Inflammation
Online Access:https://doi.org/10.1172/jci.insight.141640

Internet

https://doi.org/10.1172/jci.insight.141640

Similar Items